Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, noviembre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
DataMEDS AI Inc
MEDS
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.34
0.61
84.14%
al cierre: Nov 20, 4:00 PM EST
$1.55
0.21
15.67%
After hour: Nov 20, 7:59 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
DataMEDS AI (MEDS) Stock Price Target 2026
See analyst price targets, ratings and recent upgrades and downgrades for DataMEDS AI (MEDS) stock.
People Also Watch
McKesson Corp
NYSE:MCK
$1070
0.05%
Cencora Inc
NYSE:COR
$339
-0.03%
Cardinal Health Inc
NYSE:CAH
$272.81
-%
Henry Schein Inc
NASDAQ:HSIC
$83.37
-0.18%
AdaptHealth Corp
NASDAQ:AHCO
$7.2
-%
Akso Health Group
NASDAQ:AHG
$1.28
1.59%
Pomdoctor Ltd
NASDAQ:POM
$1.5
-11.46%
Cosmos Health Inc
NASDAQ:COSM
$2.93
4.27%
ZeroStack Corp
NASDAQ:ZSTK
$2.75
-1.79%
NYSE:ACH
$0.13
-%
No data available
Muestra todas las empresas relacionadas con 10
Fusiones y adquisiciones:
Todos Medical Ltd announced it will sell assets to DataMEDS AI (MEDS) on Thursday, November 19, 2026
Loading...
Loading watchlists...
Analyst Ratings News
PRO
EF Hutton Assumes Trxade Health at Buy, Announces Price Target of $1.25
EF Hutton analyst Fozia Ahmed assumes Trxade Health (NASDAQ:MEDS) with a Buy rating and announces Price Target of $1.25.
Benzinga Newsdesk
PRO
EF Hutton Maintains Buy on Trxade Health, Lowers Price Target to $1.25
EF Hutton analyst Constantine Davides maintains Trxade Health (NASDAQ:MEDS) with a Buy and lowers the price target from $1.7 to $1.25.
Benzinga Newsdesk
PRO
Maxim Group Maintains Buy on Trxade Health, Lowers Price Target to $1.75
Maxim Group analyst Allen Klee maintains Trxade Health (NASDAQ:MEDS) with a Buy and lowers the price target from $2.5 to $1.75.
Benzinga Newsdesk
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.
Benzinga Insights
PRO
EF Hutton Initiates Coverage On Trxade Health with Buy Rating, Announces Price Target of $4.5
EF Hutton analyst Constantine Davides initiates coverage on Trxade Health (NASDAQ:MEDS) with a Buy rating and announces Price Target of $4.5.
Benzinga Newsdesk
Benzinga's Top Upgrades, Downgrades For December 3, 2020
Upgrades
Benzinga Insights